JPRN-jRCT2051230108招募中1 期
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects with Relapsed and Refractory Multiple Myeloma
Hayakawa Jin0 个研究点目标入组 12 人开始时间: 2023年10月4日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •History of multiple myeloma with relapsed and refractory disease
- •-Eastern Cooperative Oncology Group Performance Status of 0 or 1
- •-Must have measurable disease as determined by the central laboratory
排除标准
- •-Symptomatic central nervous system involvement of multiple myeloma
- •-Prior autologous stem cell transplant <= 3 months prior
- •-Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning <= 12 months prior
- •-History of concurrent second cancers requiring active, ongoing systemic treatment
研究者
相似试验
招募中
不适用
A Phase 1b, open-label, dose-finding study of CC-90010 in combination with temozolomide with or without radiation therapy in subjects with newly diagnosed glioblastomaGliomaGlioblastomaNL-OMON54644Celgene Corporation36
招募中
不适用
A phase 1b, dose finding, open label study of the safety and tolerability of carboplatin-cyclophosphamide combined with atezolizumab, an antibody that targets programmed death ligand 1 (PD-L1), in patients with advanced breast cancer, ovarian, cervical and endometrial cancer.breast cancerNL-OMON45572ederlands Kanker Instituut12
进行中（未招募）
不适用
A phase Ib study to determine the maximum starting dose and to evaluate safety, pharmacokinetic and efficacy profiles of INC424 in myelofibrosis patients who have thrombocytopenia.EUCTR2010-023055-29-NLovartis Pharma Services AG62
进行中（未招募）
不适用
A Phase Ib, open-label, dose-finding study of the JAK inhibitor INC424 tablets administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) and baseline platelet counts = 50 x109/L and <100 x109/Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)MedDRA version: 14.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023055-29-ATovartis Pharma Services AG62
进行中（未招募）
不适用
A Phase Ib, open-label, dose-finding study of the JAK inhibitor INC424 tablets administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) and baseline platelet counts = 50 x109/L and <100 x109/EUCTR2010-023055-29-GBovartis Pharma Services AG62